DTC Biotech

DTC Biotech is a clinical-stage biotechnology company based in Shenzhen, China, specializing in the development of next-generation cell therapies and mRNA-based therapeutics. The company focuses on leveraging its proprietary DTC-CAR-T platform to create highly efficient and safer treatments for hematological malignancies, solid tumors, and autoimmune diseases. Their pipeline includes several CAR-T candidates targeting CD19 and BCMA, with a particular emphasis on optimizing cell persistence and reducing toxicity. DTC Biotech also explores mRNA technology and lipid nanoparticle (LNP) delivery systems to expand its therapeutic reach into vaccines and protein replacement therapies.